Actionnariat et activité des initiés pour Anavex Life Sciences Corp. (AVXL): transactions des initiés, déclarations de trading du Sénat et de la Chambre américaine et actions en circulation. Suivez comment dirigeants et politiciens négocient le titre.
Prix
| Prix | $2.36 |
| Capitalisation | $219M |
| Bourse | NASDAQ |
| Pays | US |
Bilan (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | $9.2M | $27.4M | $22.9M | $22.2M | $29.2M | $152.1M | $149.2M | $151.0M | $132.2M | $102.6M |
| Placements à Court Terme | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Créances | $79347 | $9748 | $1.9M | $2.6M | $4.8M | $9.1M | $3.2M | $2.7M | $2.4M | $809000 |
| Stocks | 0 | 0 | 0 | -$2.6M | 0 | $16365 | 0 | 0 | 0 | 0 |
| Actifs Courants | $9.4M | $27.8M | $24.3M | $25.3M | $34.5M | $161.6M | $152.7M | $154.4M | $135.6M | $103.8M |
| Immobilisations Corporelles | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Incorporels | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Totaux | $9.5M | $27.8M | $24.4M | $25.3M | $34.5M | $161.6M | $152.7M | $154.4M | $135.6M | $103.8M |
| Dettes Fournisseurs | $3.1M | $3.6M | $3.0M | $3.5M | $4.0M | $4.7M | $3.8M | $4.3M | $9.6M | $4.2M |
| Dette à Court Terme | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Passifs Courants | $3.2M | $3.6M | $3.9M | $5.0M | $7.3M | $10.8M | $10.2M | $12.5M | $15.3M | $8.9M |
| Dette à Long Terme | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Passifs Totaux | $3.2M | $3.6M | $3.9M | $5.0M | $7.3M | $10.8M | $10.2M | $12.5M | $15.3M | $8.9M |
| Réserves | -$78.0M | -$91.5M | -$108.9M | -$133.4M | -$159.7M | -$197.6M | -$245.6M | -$293.1M | -$336.1M | -$382.4M |
| Capitaux Propres | $6.3M | $24.3M | $20.5M | $20.3M | $27.2M | $150.8M | $142.5M | $141.9M | $120.3M | $94.9M |
| Dette Totale | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dette Nette | -$9.2M | -$27.4M | -$22.9M | -$22.2M | -$29.2M | -$152.1M | -$149.2M | -$151.0M | -$132.2M | -$102.6M |
| Fonds de Roulement | $6.3M | $24.2M | $20.4M | $20.3M | $27.2M | $150.8M | $142.5M | $141.9M | $120.3M | $94.9M |
Santé financière
| Dette / Capitaux propres | 0.00 |
| Ratio de liquidité | 15.62 |
Rentabilité
| Rentabilité des capitaux propres | -21.11% |
| Rentabilité du capital investi | -27.25% |
| Rentabilité des actifs | -20.01% |
| Marge brute | 0.00% |
| Marge opérationnelle | 0.00% |
| Marge nette | 0.00% |
Entreprises liées: ABSI · ARVN · ATXS · CTMX · ERAS · MBX · MGTX
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de AVXL: Vue d'ensemble · Financiers · Valorisation · Statistiques · Estimations · Technique · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions